Beijing Meidi Kangxin Pharmaceutical Technology

Beijing Meidi Kangxin Pharmaceutical Technology is a specialized Contract Research Organization (CRO) that provides comprehensive clinical research and regulatory services to the pharmaceutical and medical device industries. Founded in 2008 and headquartered in Beijing, the company offers expertise in drug registration, clinical trial design, and project management for Phase I through IV studies. In 2015, the firm was acquired by Hangzhou Tigermed Consulting, significantly expanding its resources and integration within the global clinical development landscape. Meidi Kangxin is particularly noted for its deep understanding of China's National Medical Products Administration (NMPA) regulations, helping clients accelerate the market entry of new therapies. The company serves a diverse portfolio of domestic and international clients, ensuring compliance and high-quality data standards in clinical development.